Phase II trial of taxol in salivary gland malignancies (E1394): A trial of the Eastern Cooperative Oncology Group

Head and Neck

Volumn 28, Issue 3, 2006, Pages 197-204

  Gilbert, Jill ^a   Li, Yi ^b   Pinto, Harlan A ^c   Jennings, Timothy ^d   Kies, Merrill S ^e,f   Silverman, Paula ^g   Forastiere, Arlene A ^h  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Adenocarcinoma; Adenoid cystic; Mucoepidermoid; Paclitaxel taxol; Salivary gland tumor

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL;

ADENOCARCINOMA; ADENOID CYSTIC CARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ANAPHYLAXIS; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DYSPNEA; FATIGUE; FEMALE; FLU LIKE SYNDROME; FLUSHING; GRANULOCYTOPENIA; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOTENSION; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; MALE; METABOLIC DISORDER; NEUTROPENIA; NEUTROPHIL COUNT; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SALIVARY GLAND CARCINOMA; SIDE EFFECT; SKIN TOXICITY; SURVIVAL RATE; THORAX PAIN; THROMBOCYTOPENIA; VISUAL DISORDER; WEIGHT GAIN;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, ADENOID CYSTIC; CARCINOMA, MUCOEPIDERMOID; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; SALIVARY GLAND NEOPLASMS;

EID: 33144486272     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20327     Document Type: Article

References (25)

1. Skarsgard DP, Groome A, Mackillop WJ, et al. Cancers of the upper aerodigestive tract in Ontario, Canada and the United States. Cancer 2000;88:1728-1738.
2. Jones AS, Hamilton JW, Rowley H, et al. Adenoid cystic carcinoma of the head and neck. Clin Otolaryngol 1997;22:434-443.
3. Speight PM, Barrett AW. Salivary glands and saliva. Oral Dis 2002;8:229-240.
4. Spiro RH, Huvos AG, Strong EW. Adenocarcinoma of salivary origin: clinicopathologic study of 204 patients. Am J Surg 1982;144:423-431.
5. Bailey BJ, Johnson JT, Kohut RI, Pillsbury HC, Tardy ME, editors. Head and neck surgery-otolaryngology. Philadelphia: J.B. Lippincott Company; 1993.
6. Licitra L, Marchini S, Spinaze S, et al. Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. Cancer 1991;68:1874-1877.
7. Creagan ET, Woods JE, Rubin J, et al. Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck. Cancer 1988;62:2313-2319.
8. Airoldi M, Bumma C, Bertetto O, et al. Vinorelbine treatment of recurrent salivary gland carcinoma. Bull Cancer 1998;85:892-894.
9. Alberts DS, Manning MR, Coulthard SW, et al. Adriamycin/cis-platinum/ cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland. Cancer 1981;47:645-648.
10. Dreyfuss AL, Clark JR, Fallon BG, et al. Cyclophosphamide, doxorubicin and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer 1987;60:2869-2872.
11. Venook AP, Tseng A, Myers FJ, et al. Cisplatin, doxorubicin and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol 1987;5:951-955.
12. Airoldi M, Pedani F, Succo G, et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 2001;91:541-547.
13. Milross CG, Mason KA, Hunter NR, et al. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 1996;88:1308-1314.
14. Piechocki MP, Lonardo F, Ensley JF, et al. Anticancer activity of docetaxel in murine salivary gland carcinoma. Clin Cancer Res 2002;8:870-877.
15. Agresti A. Categorical data analysis. New York: Wiley; 1990.
16. Bahadur RR. Stochastic comparison of tests. Ann Math Stat 1960;31:276-295.
17. Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc 1958;53:457-481.
18. Vered M, Braunstein E, Buchner A. Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck 2002;24:632-636.
19. Yamada K, Iwai K, Okada Y, et al. Immunohistochemical expression of epidermal growth factor receptor in salivary gland tumours. Virch Arch A Pathol Anat Histopathol 1989;415:523-531.
20. Edwards PC, Bhuiya T, Kelsch RD. C-kit expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and monomorphic adenoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;95:586-593.
21. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-2622.
22. Lin YC, Brown K, Diebenlist U. Activation of NF-κB requires proteolysis of the inhibitor Iκβ-α: signal-induced phosphorylation of Iκβ-a alone does not release active NF-κβ. Proc Natl Acad Sci U S A 1995;92:552-556.
23. Azuma M, Yamashita T, Aota K, et al. 5-Fluorouracil suppression of NF-κβ is mediated by the inhibition of Iκβ kinase activity in human salivary gland cancer cells. Biochem Biophys Res Comm 2001;282:292-296.
24. Glisson B, Colevas AD, Haddad R, et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res 2004;10:944-946.
25. Nguyen LH, Black MJ, Hier M, et al. HER2/neu and Ki-67 as prognostic indicators in mucoepidermoid carcinoma of salivary glands. J Otolarlyngol 2003;32:328-331.